Profile data is unavailable for this security.
About the company
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
- Revenue in USD (TTM)6.95bn
- Net income in USD1.30bn
- Incorporated1999
- Employees18.10k
- LocationAgilent Technologies Inc5301 Stevens Creek BlvdSANTA CLARA 95051United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.agilent.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Steris PLC | 5.83bn | 708.66m | 24.00bn | 17.79k | 34.05 | 3.35 | 20.04 | 4.12 | 7.19 | 7.18 | 59.09 | 72.93 | 0.5658 | 4.92 | 6.12 | 327,662.40 | 6.91 | 5.04 | 7.59 | 5.51 | 44.11 | 43.75 | 12.21 | 10.69 | 1.75 | 20.99 | 0.2094 | 37.51 | 6.24 | 12.49 | 10.64 | 8.40 | 11.52 | 8.99 |
| DexCom Inc | 4.52bn | 720.70m | 26.58bn | 10.30k | 38.54 | 9.75 | 27.54 | 5.89 | 1.77 | 1.77 | 11.08 | 6.99 | 0.6519 | 3.02 | 4.28 | 438,436.90 | 10.40 | 8.79 | 16.41 | 11.75 | 60.20 | 64.97 | 15.96 | 14.90 | 1.38 | -- | 0.4785 | 0.00 | 11.34 | 22.27 | 6.41 | 41.63 | 14.79 | -- |
| Veeva Systems Inc | 3.08bn | 860.33m | 30.74bn | 7.29k | 36.37 | 4.36 | 34.16 | 9.98 | 5.14 | 5.14 | 18.41 | 42.84 | 0.4234 | -- | 9.15 | 422,472.40 | 11.83 | 11.33 | 13.50 | 14.35 | 75.67 | 72.60 | 27.93 | 23.96 | -- | -- | 0.00 | 0.00 | 16.20 | 19.99 | 35.84 | 18.85 | 36.56 | -- |
| Waters Corp | 3.17bn | 642.63m | 32.07bn | 7.60k | 30.38 | 12.52 | 37.77 | 10.13 | 10.77 | 10.77 | 53.03 | 26.11 | 0.6569 | 2.46 | 4.05 | -- | 13.34 | 17.03 | 14.53 | 20.68 | 59.28 | 59.01 | 20.30 | 22.40 | -- | 16.77 | 0.3546 | -- | 6.99 | 6.00 | 0.7518 | 4.26 | -8.14 | -- |
| GE HealthCare Technologies Inc | 20.63bn | 2.09bn | 36.10bn | 54.00k | 17.40 | 3.48 | 13.22 | 1.75 | 4.55 | 4.55 | 45.03 | 22.77 | 0.5893 | 5.93 | 4.31 | 381,944.40 | 6.15 | 6.70 | 8.46 | 9.25 | 39.98 | 40.44 | 10.44 | 10.49 | 1.13 | 9.97 | 0.4866 | 1.85 | 4.84 | 3.74 | 4.57 | 0.7558 | 13.23 | -- |
| Agilent Technologies Inc | 6.95bn | 1.30bn | 36.49bn | 18.10k | 28.26 | 5.42 | 22.93 | 5.25 | 4.56 | 4.56 | 24.34 | 23.82 | 0.5655 | 3.29 | 4.94 | 383,867.40 | 10.61 | 11.44 | 12.82 | 13.67 | 52.73 | 53.25 | 18.75 | 18.82 | 1.52 | 18.30 | 0.3322 | 20.76 | 6.73 | 5.41 | 1.09 | 12.63 | 27.88 | 7.10 |
| Resmed Inc | 5.40bn | 1.49bn | 38.39bn | 10.60k | 26.05 | 6.07 | 22.71 | 7.11 | 10.12 | 10.12 | 36.75 | 43.39 | 0.6901 | 2.34 | 5.53 | 509,256.50 | 19.00 | 15.33 | 21.94 | 17.76 | 60.85 | 57.29 | 27.53 | 21.96 | 2.32 | -- | 0.095 | 28.94 | 9.84 | 11.72 | 37.20 | 17.64 | -1.02 | 1.69 |
| Edwards Lifesciences Corp | 5.88bn | 1.34bn | 44.71bn | 15.80k | 33.76 | 4.38 | 29.94 | 7.60 | 2.28 | 2.33 | 10.01 | 17.57 | 0.4484 | 1.14 | 8.35 | 372,392.40 | 10.19 | 14.52 | 11.81 | 16.61 | 78.19 | 79.01 | 22.72 | 25.54 | 3.29 | -- | 0.0554 | 0.00 | 8.57 | 4.58 | 14.55 | 5.94 | 0.2857 | -- |
| Becton Dickinson and Co | 21.92bn | 1.76bn | 48.88bn | 72.00k | 28.06 | 1.93 | 11.57 | 2.23 | 6.12 | 6.12 | 76.34 | 88.79 | 0.4004 | 2.96 | 8.52 | 304,500.00 | 3.21 | 3.00 | 3.78 | 3.48 | 46.42 | 45.58 | 8.01 | 8.20 | 0.5826 | 6.68 | 0.4359 | 66.89 | 8.24 | 6.32 | -1.58 | 46.93 | -0.2352 | 5.65 |
| IDEXX Laboratories Inc | 4.30bn | 1.06bn | 51.63bn | 11.00k | 49.43 | -- | 56.25 | 12.00 | 13.08 | 13.08 | 53.12 | -- | -- | -- | -- | 391,245.60 | -- | 28.96 | -- | 43.58 | 61.80 | 60.30 | 24.62 | 22.86 | -- | 37.95 | -- | -- | 10.42 | 9.72 | 19.33 | 12.74 | 2.94 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 31.31m | 11.04% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 14.95m | 5.27% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 12.44m | 4.39% |
| Massachusetts Financial Services Co.as of 31 Dec 2025 | 11.94m | 4.21% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 8.59m | 3.03% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2025 | 8.15m | 2.87% |
| Geode Capital Management LLCas of 30 Sep 2025 | 7.40m | 2.61% |
| Generation Investment Management LLPas of 30 Sep 2025 | 6.36m | 2.24% |
| BlackRock Investment Management (UK) Ltd.as of 30 Sep 2025 | 4.83m | 1.70% |
| Pictet Asset Management SAas of 31 Dec 2025 | 4.66m | 1.65% |
